Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START)



Status:Completed
Conditions:Hospital, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases, Other
Healthy:No
Age Range:18 - Any
Updated:10/24/2018
Start Date:March 15, 2014
End Date:February 9, 2018

Use our guide to learn which trials are right for you!

Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study to assess
the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal
Stem Cells infusion in patients with Acute Respiratory Distress Syndrome (ARDS). This study
is the extension of the Phase 1 pilot study (NCT01775774). Patients will be randomized to
receive Human Mesenchymal Stem Cells infusion or placebo in a 2:1 allocation. Patients will
be followed daily for adverse events through day 28, death or hospital discharge, whichever
occurs first. Vital status will be collected at 6 and 12 months after study enrollment.

We carried out a randomized, double-blind placebo-controlled trial on allogeneic bone marrow
derived mesenchymal stromal cells for treatment of moderate to severe ARDS in 60 patients, 40
MSC and 20 placebo, in a 2:1 randomization. The primary endpoint was safety. The results
showed no safety issues. Secondary endpoints for clinical and biological variables were
studied as well. Plasma Ang-2 significantly decline in the MSC treated group compared to the
Placebo patients. There were no other significant differences in the other secondary
endpoints.

Inclusion Criteria:

Patients will be eligible for inclusion if they meet all of the below criteria. Criteria
1-3 must all be present within a 24-hour time period and at the time of enrollment:

Acute onset (defined below) of:

1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a
PaO2/FiO2 ratio < 200 with at least 8 cm H2O positive end-expiratory airway pressure
(PEEP)

2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph

3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.

Exclusion Criteria:

1. Age less than 18 years

2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of
ARDS

3. Pregnant or breast-feeding

4. Prisoner

5. Presence of any active malignancy (other than non-melanoma skin cancer) that required
treatment within the last 2 years

6. Any other irreversible disease or condition for which 6-month mortality is estimated
to be greater than 50%

7. Moderate to severe liver failure (Childs-Pugh Score > 12)

8. Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen

9. Patient, surrogate, or physician not committed to full support (exception: a patient
will not be excluded if he/she would receive all supportive care except for attempts
at resuscitation from cardiac arrest)

10. Major trauma in the prior 5 days

11. Lung transplant patient

12. No consent/inability to obtain consent

13. Moribund patient not expected to survive 24 hours

14. WHO Class III or IV pulmonary hypertension

15. Documented deep venous thrombosis or pulmonary embolism within past 3 months

16. No arterial line/no intent to place an arterial line

17. No intent/unwillingness to follow lung protective ventilation strategy or fluid
management protocol

18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory
ventilation (HFOV)
We found this trial at
6
sites
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: Joseph E Levitt, MD
Phone: 650-723-7409
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Taylor B Thompson, MD
Phone: 617-726-3498
?
mi
from
Boston, MA
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Michael Donahoe, MD
Phone: 412-624-7441
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Phone: 614-247-7716
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Saint Paul, Minnesota 55108
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Michael A Matthay, MD
Phone: 415-353-1206
?
mi
from
San Francisco, CA
Click here to add this to my saved trials